Vega has a solid scientific background in molecular biology, bacterial and viral pathogenesis, toxins, structural bioinformatics, computational biology, and vaccinology. She has spent more than 20 years in the R&D of large pharmaceutical companies (Chiron Vaccines, Novartis Vaccines, and GSK), mainly working the infectious disease area. She served as Discovery Project Leader and Vaccine Development Leader on multiple vaccine programs, with a special interest in meningococcal and pneumococcal vaccines. In these roles, she was involved in setting the program strategy, ensuring operational execution and coordinating team’s effort toward common objectives. She significantly contributed to the initial design and clinical development of 4CMenB, the first serogroup B meningococcal vaccine, which is now licensed in more than 50 countries all over the word. Vega holds a degree in Pharmaceutical Chemistry and a PhD in Biotechnology. She has published more than 70 scientific papers and reviews on bacterial pathogenesis, antigen characterization, and vaccine development and has participated as a speaker at several international conferences.